Eosinophilic otitis media: a new middle ear disease entity
- PMID: 18940145
- DOI: 10.1007/s11882-008-0096-5
Eosinophilic otitis media: a new middle ear disease entity
Abstract
Eosinophilic otitis media (EOM) is intractable otitis media characterized by the presence of a highly viscous yellow effusion containing eosinophils. It occurs mainly in patients with bronchial asthma and is resistant to conventional treatments for otitis media. Here we discuss the clinical features, pathogenesis, and management of EOM. EOM predominantly affects women and presents most often in patients in their 50s. The clinical features of the middle ear in EOM are roughly divided into the otitis media with effusion type and chronic otitis media type. The latter is further divided into two subtypes: simple perforation and granulation tissue formation. EOM is often complicated by rhinosinusitis (eosinophilic sinusitis). High-tone loss is more frequently found and more severe in EOM patients than in chronic otitis media control patients, and EOM patients sometimes become deaf suddenly. Systemic or topical steroid administration is the most effective treatment for patients with EOM. The instillation of triamcinolone acetonide, a suspension of steroids, into the middle ear is very effective for controlling eosinophilic inflammation. It is very important to explain to patients with EOM that the disease may last for a long period and that progressive and sudden hearing loss may occur.
Similar articles
-
New Insights into Eosinophilic Otitis Media.Curr Allergy Asthma Rep. 2015 Dec;15(12):76. doi: 10.1007/s11882-015-0577-2. Curr Allergy Asthma Rep. 2015. PMID: 26546407 Review.
-
Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma.Ann Allergy Asthma Immunol. 2006 Dec;97(6):761-6. doi: 10.1016/S1081-1206(10)60967-2. Ann Allergy Asthma Immunol. 2006. PMID: 17201235 Clinical Trial.
-
Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.Clin Exp Allergy. 2005 Oct;35(10):1370-6. doi: 10.1111/j.1365-2222.2005.02330.x. Clin Exp Allergy. 2005. PMID: 16238798
-
Antigen-specific IgE in middle ear effusion of patients with eosinophilic otitis media.Ann Allergy Asthma Immunol. 2014 Jul;113(1):88-92. doi: 10.1016/j.anai.2014.04.021. Epub 2014 May 24. Ann Allergy Asthma Immunol. 2014. PMID: 24863399
-
Role of IgE in eosinophilic otitis media.Allergol Int. 2010 Sep;59(3):233-238. doi: 10.2332/allergolint.10-RAI-0223. Epub 2010 Jul 25. Allergol Int. 2010. PMID: 20657163 Review.
Cited by
-
Eosinophilic Otitis Media: Modern Aspects of Pathogenesis, Clinical Features, Diagnosis and Treatment.Indian J Otolaryngol Head Neck Surg. 2022 Aug;74(Suppl 1):132-140. doi: 10.1007/s12070-020-01903-z. Epub 2020 Jun 18. Indian J Otolaryngol Head Neck Surg. 2022. PMID: 36032916 Free PMC article.
-
Utilizing temporal imaging to enhance early diagnosis of eosinophilic otitis media in clinical practice.Eur Arch Otorhinolaryngol. 2025 May 1. doi: 10.1007/s00405-025-09388-8. Online ahead of print. Eur Arch Otorhinolaryngol. 2025. PMID: 40310521
-
Cochlear implantation in deaf patients with eosinophilic otitis media using subtotal petrosectomy and mastoid obliteration.Eur Arch Otorhinolaryngol. 2017 Feb;274(2):1173-1177. doi: 10.1007/s00405-016-4091-5. Epub 2016 May 11. Eur Arch Otorhinolaryngol. 2017. PMID: 27168402
-
Intractable middle ear effusion in EGPA patients might cause permanent hearing loss: a case-control study.Allergy Asthma Clin Immunol. 2022 Aug 6;18(1):68. doi: 10.1186/s13223-022-00706-x. Allergy Asthma Clin Immunol. 2022. PMID: 35933390 Free PMC article.
-
New Insights into Eosinophilic Otitis Media.Curr Allergy Asthma Rep. 2015 Dec;15(12):76. doi: 10.1007/s11882-015-0577-2. Curr Allergy Asthma Rep. 2015. PMID: 26546407 Review.